Panel, Conference Presentation
World-class Healthcare: Investing in Biomedical Innovation
- Longitudinal studies tracking 20,000 Emiratis aim to identify drivers of chronic disease, while global learning about living systems has accelerated, with more knowledge gained in the last 20 years than in the preceding 300,000.
- Technological costs in hard sciences like genomics have decreased faster than Moore's Law, with full genome sequencing now costing under $10,000 and full exome sequencing under $100, enabling faster company formation and drug discovery.
- AI and deep learning are projected to become relevant within five years, specifically for protein design and 3D protein folding, though current algorithms lack sufficient structured, computable data sets to solve complex biological problems effectively.
- Venture capital firms are prioritizing rare disease states affecting 1,000 to 5,000 patients where $30 million can secure Phase I or II answers and FDA accelerated approval, yet less than 5% of pipelines address cardiovascular disease, the leading killer, due to its requirement for massive clinical studies.
- Large pharmaceutical companies face constraints from shareholder returns and internal silos, with a strategy relying on PD-1 Opdivo and IO-IO combinations predicted to underperform relative to hopes, while 65% of FDA-approved drugs are externally developed yet pharma launches 69% of new approvals.
- The Parker Foundation is transitioning from basic science grants to investing $15 to $30 million in seed-stage companies and conducting Phase I clinical trials internally to overcome translational barriers, addressing a scarcity of capital for moving research to patients.
- Industry experts predict that over the next 20 years, biotech companies will address major diseases, while over 50 years, healthcare spending could reach 50% to 60% of GDP, driven by new therapies like CRISPR-Cas9 which allows arbitrary gene editing and large DNA insertions.
- Significant infrastructure and policy challenges remain, including a lack of mechanisms to track outcomes for next-gen therapies, the need to restructure insurance and government systems for value, and a projected 15 to 20-year timeline for widespread genomic screening of newborns.
- M&A activity is viewed as a beneficial catalyst for entrepreneurship, with exits occurring within three to six months of sale to fund new ventures, though the future requires digital models of biological systems to achieve complex in silico understanding and potential disease eradication.
- Data utility is currently limited by unstructured physician notes and varying global ownership laws, though the ecosystem is expected to expand with standardized tools as seen in the tech industry's growth, creating platforms where progress by one entity lifts all others.